AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails
Farxiga’s Safety Profile Undented
Executive Summary
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.